FDA
-
-
-
-
-
-
-
Alkermes increases Avadel acquisition offer to $22.50 per share
-
-
-
-
-
-
-
Alkermes plc Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
-
-
-
-
-
-
-
Alkermes plc Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Alkermes plc Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Alkermes (ALKS) Issues Letter to Shareholders
-
-
-
-
-
-
-
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

